Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Amygdala Neurosciences","sponsor":"National Institute on Alcohol Abuse and Alcoholism","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amygdala Neurosciences Awarded $2.0 Million NIH Grant to Conduct IND Enabling Studies","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Amygdala Neurosciences","sponsor":"ABMRF","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ABMRF Invests in Amygdala Neurosciences to Develop ANS-858 for Alcohol Use Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by Amygdala Neurosciences

    Menu

    Amygdala Neurosciences

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Amygdala Neurosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ABMRF Invests in Amygdala Neurosciences to Develop ANS-858 for Alcohol Use Disorder

              Details:

              The financing aims to fund the clinical development of the company-lead product ANS-858, which is investigating in the early-stage clinical trial for the treatment of patients with alcohol use disorder.

              Lead Product(s): ANS-858

              Therapeutic Area: Psychiatry/Psychology Product Name: ANS-858

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: ABMRF

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing May 14, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Amygdala Neurosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Amygdala Neurosciences Awarded $2.0 Million NIH Grant to Conduct IND Enabling Studies

              Details:

              The funding will support the IND-enabling and early-stage development of selective, reversible, orally bioavailable ALDH2 inhibitor ANS-858 to treat alcohol use disorder.

              Lead Product(s): ANS-858

              Therapeutic Area: Psychiatry/Psychology Product Name: ANS-858

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: National Institute on Alcohol Abuse and Alcoholism

              Deal Size: $2.0 million Upfront Cash: Undisclosed

              Deal Type: Funding August 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY